Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04358497
Other study ID # TR001
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date October 1, 2020
Est. completion date October 1, 2022

Study information

Verified date April 2020
Source Hospital de Clínicas Dr. Manuel Quintela
Contact Sebastian Sarutte, VS
Phone +59899533449
Email ssarutte1@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Compare the efficacy and safety of endovascular treatment with sandwich technique (controlled release coils and 2% polidocanol foam) associated with diosmin-hisperidine and ibuprofen medical treatment and only the best chronic medical treatment available diosmin-hisperidine and ibuprofen for 3 months, in women of active gynecological age carrying pelvic congestion syndrome in public assistance in Montevideo, Uruguay.


Description:

Pelvic congestion syndrome (PCS) is a recognized and frequent cause of Chronic Pelvic Pain (10% to 30%). It is defined as the presence of chronic symptoms, which may include pelvic pain, perineal heaviness, urinary urgency and postcoital pain, caused by reflux and / or obstruction of the gonadic and / or pelvic veins, and that may be associated with vulvar, perineal and lower limbs varicose veins.

There is no standard approach to managing PCS. According to expert recommendations, therapies should be individualized according to the patient's symptoms and needs.

Medical treatment options include progestagens, danazol, combined oral hormonal contraceptives, phlebotonics such as hisperidine-added diosmin, non-steroidal anti-inflammatory drugs and gonadotropin-releasing hormone (GnRH) agonists

Currently, the only accepted chronic medical treatment is the association of non-steroidal and phlebotonic anti-inflammatories, but they have shown a poor symptomatic benefit in reducing pain.

Surgical treatment has evolved over time mainly in the hands of laparoscopic techniques, currently the endovascular option is the most widely accepted for presenting excellent long-term results with abolition of pain in up to 90% at 2 years.

HYPOTHESIS

Endovascular treatment of pelvic congestion syndrome is better in terms of pain control and quality of life compared to drug treatment.

General objective

Compare the efficacy and safety of endovascular treatment with sandwich technique (controlled release coils and 2% polidocanol foam) associated with diosmin-hisperidine and ibuprofen medical treatment and only the best chronic medical treatment available diosmin-hisperidine and ibuprofen for 3 months, in women of active gynecological age carrying pelvic congestion syndrome in public assistance in Montevideo, Uruguay.

Specific objectives

• Compare pain in patients undergoing endovascular treatment with the best

medical treatment.

- Evaluate the persistence of pelvic varices in patients undergoing endovascular treatment of SCP.

- Compare the Female Sexual Satisfaction Index in both groups.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date October 1, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Active gynecological age

- Chronic pelvic pain diagnosed by gynecologist of at least 6 months of evolution.

- Transvaginal duplex ultrasound: presence of periuterine varicose veins defined by veins larger than 5mm in diameter with reflux greater than 0.5 seconds on Valsava maneuvers.

Exclusion Criteria:

- Presence of other causes of chronic pelvic pain: endometriosis, pelvic inflammatory disease, postoperative adhesions, uterine myoma, adenomyosis, ovarian tumors, polycystic ovary.

- Fibromyalgia

- BMI greater than 35

- Chronic kidney disease

- thrombophilia

- Alterationof coagulation.

- Allergy to iodinated contrast medium.

Study Design


Intervention

Device:
Medtronic® Concerto® detachable coil system
coil embolization of the reflux pathways
Procedure:
sclerosis
Pelvic varices sclerosis with polidocanol foam
Drug:
Diosmin / Hesperidin
Best chronic medial treatment
Ibuprofen 400 mg
NSAID treatment

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Hospital de Clínicas Dr. Manuel Quintela Centro Cardiovascular Universitario, Centro Hospitalario Pereyra Rossell, University of the Republic, Uruguay

Outcome

Type Measure Description Time frame Safety issue
Other Deep venous thrombosis by duplex ultrasound Deep venous thrombosis of the iliac or femoral axis will be reported 30 days
Primary visual analogue scale (VAS) Pain assessment 1-10 from no pain to severe 30 days
Primary visual analogue scale (VAS) Pain assessment 1-10 from no pain to severe 3 months
Primary Lattinen index chronic pain assessment 2-22 from low to high 30 days
Primary Lattinen index chronic pain assessment 2-22 from low to high 3 months
Primary McGill Pain Questionnaire subjective pain experience assessment 30 days
Primary McGill Pain Questionnaire subjective pain experience assessment 3 months
Secondary Female sexual function index questionnaire that assesses different domains of sexual function. 0-48 from no sexual distress to high level of sexual distress 30 days
Secondary Female sexual function index questionnaire that assesses different domains of sexual function. . 0-48 from no sexual distress to high level of sexual distress 3 months
Secondary varicose and reflux persistance by transabdominal duplex scan transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux 30 days
Secondary varicose and reflux persistance by transabdominal duplex scan transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux 3 months
Secondary varicose and reflux persistance by transvaginal duplex scan transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux 3 months
Secondary varicose persistance assesment by tomography angiotomography: Varicose and conadic Patency 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05633277 - Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections N/A
Completed NCT04758728 - Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping N/A
Recruiting NCT05409976 - The GORE® VIAFORT Vascular Stent IVC Study N/A
Completed NCT06395025 - Blinded User Study for the Evaluation of the Acceptability and Efficacy of One Medical Device in Venous Return in Comparison With a Control Group N/A
Completed NCT03703765 - Volume Estimation of the Limb After VEnous Treatment N/A
Completed NCT01368159 - Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein Phase 4
Recruiting NCT05628948 - Vascular Lab Resource (VLR) Biorepository
Completed NCT06153680 - Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return N/A
Terminated NCT03363633 - Perforator Vein Injection for Symptomatic Venous Disease N/A
Recruiting NCT05489588 - The GORE® VIAFORT Vascular Stent Iliofemoral Study N/A
Not yet recruiting NCT06433024 - Training of a Artificial Intelligence Model to Detect Venous Diseases Using PPG Technology
Completed NCT02655887 - BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease N/A
Recruiting NCT05050799 - US Post-Market Surveillance Study of the Surfacer System
Completed NCT01993914 - Prevalence of MTHFR Polymorphisms in Venous Disease N/A
Active, not recruiting NCT04138134 - Autophagy and Venous Endothelial Function
Terminated NCT04964817 - HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study
Recruiting NCT02139085 - Great Saphenous Vein Electrocoagulation Phase 2
Completed NCT01509599 - Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation Phase 1/Phase 2
Terminated NCT03630185 - A Comparison of Custom-manufactured vs. Off-the-rack (OTR) Compression Hosiery for Initial Management of Venous Disease N/A